A Research Opportunity Announcement (ROA) is a public document that announces the availability of an Other Transaction (OT). It provides the initiative’s purpose, type of award, instructions on how to apply, due date for proposals or applications, and research opportunity number.
Information about Other Transactions can be found on the NIH Grants & Funding website.
|Title||OTA Number||Purpose||OTA Category||Contact|
|HEAL Initiative: EPPIC-Net Pain Research Asset Application (OT2)||OTA-22-002||The purpose of this research opportunity announcement (ROA) is to invite Stage 1 preliminary applications for submission of therapeutics, including but not limited to, drugs, biologics, and devices as well as biomarkers (termed assets) for study in the HEAL Initiative’s EPPIC-Net.||HEAL/EPPIC-Net||Barbara Karp, MD|
|HEAL Initiative: EPPIC-Net Pain Research Asset Application- Dossier||OTA-23-005||The purpose of this research opportunity announcement (ROA) is to invite Stage 2 Dossier applications for submission of assets that have successfully passed Stage 1 preliminary application review. EPPIC-Net applications are reviewed in a three-stage process. applications to Stages 2 & 3 will be by invitation only.||HEAL/EPPIC-Net||Barbara Karp, MD|
|HEAL Initiative: EPPIC-Net Pain Research – Application for Clinical Trials and Related activities (OT2)||OTA-23-006||The purpose of this research opportunity announcement (ROA) is to fund early phase clinical trials of pain therapeutic assets and its related activities. The ROA accepts applications from the EPPIC-Net CCC, working in conjunction with the EPPIC-Net DCC and SCCs, for funding of clinical trial preparatory activities not covered by EPPIC-Net U24 agreements to the CCC, DCC, or Specialized Clinical Centers (Hubs/Spokes), as well as applications for specific clinical trials.||HEAL/EPPIC-Net||Barbara Karp, MD|
|Coordinating Center for the Amyotrophic Lateral Sclerosis Clinical Research Consortium||OTA-23-010||With this ROA, NINDS is soliciting applications for the Coordinating Center (CC). The CC will provide the overall scientific, administrative, and organizational leadership to accomplish the goals of ALS Clinical Research Consortium. The CC will also oversee the activities of the clinical sites, oversee and integrate ALS biospecimen and data collections, foster communication within the Consortium and with external stakeholders, as well as closely collaborate with the central data portal.||Lumy Sawaki-Adams, MD, PhD|
|Platform Trials of Thrombectomy in Acute Stroke – Application to implement the master protocol with indication expansion in the StrokeNet Thrombectomy Platform (STEP)||OTA-23-009||The purpose of this research opportunity announcement (ROA) is to fund the full implementation of the STEP platform and provide funding to initiate domain trials to expand the indications of endovascular therapy. The application will implement an FDA-approved master protocol and provide the infrastructure organization within the NIH StrokeNet to conduct future STEP domain platform trials.||Scott Janis, PhD|
|Gene Therapy Consortium (GTC) for Gene-based Clinical Trials Conducted within NeuroNEXT (OT2)||OTA-23-012||The purpose of this research opportunity announcement (ROA) is to fund the establishment and operation of a Gene Therapy Consortium that provides advice on gene-based and gene-targeted therapies proposed for clinical trials conducted within the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT).||NeuroNext||Joan Ohayon RN, MSN, CRNP, MSCN|